GenrAb Expands its Exclusive License and Sponsored Research Agreements with UTSW
GenrAb has expanded its Exclusive world-wide License from the University of Texas Southwestern (UTSW) to include over 250 additional novel anti-neuronal fully human antibodies (Abs). These Abs are now part of GenrAb’s growing therapeutic pipeline of >500 novel anti neuronal antibodies that are being screened and prioritized. These new antibodies were identified in the laboratory of Dr. Nancy Monson (UTSW) based on using her novel Antibody Gene Signature (AGS) platform technology. By building proprietary immunogenetic models, Dr. Monson and her team are able to identify anti-neuronal antibodies which have a high likelihood of being neuroprotective and neurotherapeutic. The first group of antibodies that were prioritized and screened yielded GenrAb’s therapeutic lead antibody, TGM-010. The next tranche of approximately 100 antibodies have been cloned and are currently being screened for their binding affinity and their neuroprotective capabilities. This portfolio of fully human antibodies allows GenrAb to better understand how neurodegeneration and its causes may vary slightly from one disease of the CNS to the next.